TY  - JOUR

T1  - Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with <i>FGFR3/2</i> alterations (<i>alt</i>) in THOR-2: Cohort 2 interim analysis results.

JO  - Journal of Clinical Oncology

UR  - https://doi.org/10.1200/jco.2023.41.6_suppl.503

PY  - 2023/02/21

AU  - Catto JWF

AU  - Tran B

AU  - Master VA

AU  - Roupret M

AU  - Pignot G

AU  - Tubaro A

AU  - Shimizu N

AU  - Vasdev N

AU  - Gschwend JE

AU  - Loriot Y

AU  - Nishiyama H et al

ED  - 

DO  - DOI: 10.1200/jco.2023.41.6_suppl.503

PB  - American Society of Clinical Oncology (ASCO)

VL  - 41

IS  - 6_suppl

SP  - 503

EP  - 503

Y2  - 2025/10/31

ER  -